Phragma Therapeutics
PrivateLast Round
Grant
Jun 1, 2015
Company Overview
Phragma Therapeutics Inc is a biotechnology company developing monoclonal antibody-based therapies designed to restore blood-brain barrier integrity and enable drug delivery to the central nervous system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phragma Therapeutics Comparables
Compare Phragma Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ossianix | 89% | |
| Lys Therapeutics | 81% | |
| AbbVie | 77% |
Phragma Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 1, 2015 |
Key People
Founding team and executive leadership
Phragma Therapeutics Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 6, 2025
Grew 150% QoQ from 2 to 5 employees.
Phragma Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Phragma Therapeutics's valuation, stock price, and market status.
Is Phragma Therapeutics a public or private company?
Phragma Therapeutics is a private company.
What is the current stock price of Phragma Therapeutics?
Phragma Therapeutics is a private company with no public stock price. Caplight tracks Phragma Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Phragma Therapeutics worth (valuation)?
Valuation information for Phragma Therapeutics is not publicly available.
Can I buy Phragma Therapeutics stock?
Phragma Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Phragma Therapeutics's last funding round?
Phragma Therapeutics's most recent funding round was Grant on June 1, 2015.
Who are the main investors in Phragma Therapeutics?
Key investors in Phragma Therapeutics include Pulsalys, Bpifrance.
Will Phragma Therapeutics IPO soon?
No public IPO plans have been announced for Phragma Therapeutics.
How can I track Phragma Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Phragma Therapeutics's secondary market activity and sign up for updates.